DNA topoisomerase I drugs and radiotherapy for lung cancer

Journal of Thoracic Disease

Volumn 4, Issue 4, 2012, Pages 390-397

  Chen, Allan Y ^a,b   Chen, Patricia M T ^b   Chen, Yi Jen ^c  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Camptothecin derivative; DNA topoisomerase I (TOP1); Lung cancer; Radiation sensitizer; Radiation therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CYTOTOXICITY; DIARRHEA; DOUBLE STRANDED DNA BREAK; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG MECHANISM; ESOPHAGITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; RADIATION DOSE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING;

EID: 84866853822     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.07.12     Document Type: Review

References (60)

1. Siegel R, Naishadham D,Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Wright G, Manser RL, Byrnes G, et al. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006;61:597-603.
3. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet 2011;378:1727-40.
4. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-55.
5. Principles and Practice of Radiation Oncology. 5th ed., Perez and Brady (eds.), Philadelphia, J. B. Lippincott Co., 2004.
6. Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 2003;4:120-28.
7. "Image-Guided Radiotherapy of Lung Cancer", Cox JD, Chang JY & Komaki R, (ed.), informa, Health care Communications, 2007. Available online: http://informahealthcare.com/doi/pdf/10.3109/9780849387821
8. Kavanagh BD, Timmerman RD. eds. "Stereotactic Body Radiation Therapy". Philadelphia, Lippincott Williams Wilkins. 2005.
9. Hall EJ, Giaccia AJ. eds. Radiobiology for the Radiologist, 6th ed. Philadelphia, J. B. Lippincott Co., 2006.
10. John, Flam, Legha and Phillips, eds. "Chemoradiation: an integrated approach to cancer treatment", 1st ed, Philadelphia, J. B. Lippincott Co., 1995.
11. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleotides. J Natl Cancer Inst 1996;88: 193-1203.
12. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218.
13. Liehr, Giovanella, Verschraegen. eds. The Camptothecins - unfolding their anticancer potential., New York, Ann. N. Y. Acad. Sci., 2000.
14. Chen AY, Chou R, Shih S-J, et al. Enhancement of Radiotherapy with DNA Topoisomerase I-targeted Drugs. Crit Rev Oncol Hematol 2004;S0:111-119.
15. Chen AY, OkuniefF P, Pommier Y, et al. Mammalian DNA Topoisomerase I Mediates the Enhancement of Radiation Cytotoxicity by Camptothecin Derivatives. Cancer Res 1997;57:1529-36.
16. Chen AY, Choy H, Rothenberg ML. DNA Topoisomerase I-targeting drugs as radiation sensitizers. Oncology 1999; 13:39-46.
17. WangJC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
18. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
19. Pantazis P, Early JA, Kozielski AJ, et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 1993;53:1577-82.
20. Chen AY, Yu C, Gatto B, et al. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase 1 inhibitors. Proc Natl Acad Sci USA 1993;90:8131-35.
21. Yamashita Y, Fujii N, Murakata C, et al. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992;31:12069-75.
22. Bailly C, Riou JF, Colson P, et al. DNA cleavage by topoisomerase 1 in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 1997;36:3917-29.
23. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochem Biophys Acta 1998; 1400:107-19.
24. Choy H, Macrae R. Irinotecan and Radiation in Combined-Modality Therapy for Solid Tumors. Oncology 2001; 15:22-28.
25. Munro TR. The relative radiosensitivity of the nucleus and cytoplasm of the Chinese hamster fibroblasts. Radiat Res 1970;42:4S 1-70.
26. Radford IR. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med 1986;49:611-20.
27. Herscher LL, CookJA, Pacelli R, et al. Principles of chemoradiation: theoretical and practical considerations. Oncology 1999; 13:11-22.
28. Shih S-J, Erbele T, Chen AY. Ku86 Modulates DNA Topoisomerase I-mediated Radiosensitization, but not cytotoxicity, in Mammalian Cells. Cancer Res 2005;65: 9194-99.
29. Khanna KK, Jackson SP. DNA double strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.
30. Vedam SS, Keall PJ, Kini VR, et al. Acquiring a four-dimensional computed tomography dataset using an external respiratory signal. Phys Med Biol 2003;48:45-62.
31. Chen AY, Chen MB, Chen YJ. A millimeter miss is as good as a thousand miles: The role of accurate target localization in lung stereotactic body radiation therapy. J Thorac Dis 2012;4:109-11.
32. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-100.
33. Corradetti MN, Haas AR, Rengan R. Central-Airway Necrosis after Stereotactic Body-Radiation Therapy. N Engl J Med 2012;366:2327-29.
34. Ohri N, Dicker AP, Lawrence YR. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. IntJ Radiat Oncol Biol Phys 2012;83:385-93.
35. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7.
36. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-Une therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92.
37. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-67.
38. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N EnglJ Med 2002;346:85-91.
39. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5.
40. Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-73.
41. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol 1992;10:16-20.
42. Negoro S, Masuda N, Takada Y, et al. Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-41.
43. Saka H, Shimokata K, Yoshida S, et al. Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): A phase II study of Japan Clinical Oncology Group (JCOG9504). Proc Am Soc Clin Oncol 1997; 16:447.
44. Takeda K, Negoro S, Okishio K, et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999;79:1462-67.
45. Choy H, Chakravarthy A, Devore RF, et al. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology 2000;14:43-46.
46. Kodoh S, Kurihara N, Okishio K, et al. A phase I/II study of weekly irinotecan (CPT- 11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996;IS: 1102.
47. Takeda K, Negoro S, Tanaka M, et al. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J Clin Oncol 2011;41:2S-31.
48. Yokoyama A, Kurita Y, Saijo N, et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer 1998;78:257-62.
49. Yamada M, Kudoh S, Fukuda H, et al. Dose escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer 2002;87:258-63.
50. Graham MV, Jahanzeb M, Dresler CM, et al. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996;36:1215-20.
51. Chachoua A, Hochster H, Steinfeld A, et al. Feasibility of seven weeks concomitant topotecan (T) continuous infusion with thoracic radiation. Proc Am Soc Clin Oncol 1999;18:485a.
52. Oka M, Fukuda M, Kuba M, et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer 2002;38:1998-2004.
53. GrayJR, HainsworthJD, Burris HA, et al. Paclitaxel, carboplatin, and topotecan in the treatment of small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 2000; 19:494a.
54. GrayJR, HainsworthJD, Burris HA, et al. Paclitaxel/carboplatin/topotecan with concurrent high-dose radiation therapy (RT) for the treatment of limited stage small cell lung cancer (SCLC): a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2002;21:193 la.
55. van de Pol M, van Oosterhout AG, Wilmink JT, et al. MRI in detection of brain metastases at initial staging of small-cell lung cancer. Neuroradiology 1996;38:207-10.
56. Seute T, Leffers P, ten Velde GP, et al Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004; 100:801-06.
57. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. J Clin Oncol 2007;25:2306-12.
58. Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain mediation. A multicentre phase II study. Eur J Cancer 2002;38:2724-9.
59. Chou RH, Chen AY, Lau D. Promising role of irinotecan for the treatment of brain metastases. J Clin Neurosci 2005; 12:242-45.
60. Chen G, Huynh M, Chen A, et al. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer 2008;9:35-8.